Emerging Roles of P53 and Other Tumour-suppressor Genes in Immune Regulation

Overview

Journal Nat Rev Immunol

Specialty Allergy & Immunology

Date 2016 Nov 8

PMID 27667712

Citations 198

Authors

Cesar Munoz-Fontela

Anna Mandinova

Stuart A Aaronson

Sam W Lee

Affiliations

Soon will be listed here.

Abstract

Tumour-suppressor genes are indispensable for the maintenance of genomic integrity. Recently, several of these genes, including those encoding p53, PTEN, RB1 and ARF, have been implicated in immune responses and inflammatory diseases. In particular, the p53 tumour- suppressor pathway is involved in crucial aspects of tumour immunology and in homeostatic regulation of immune responses. Other studies have identified roles for p53 in various cellular processes, including metabolism and stem cell maintenance. Here, we discuss the emerging roles of p53 and other tumour-suppressor genes in tumour immunology, as well as in additional immunological settings, such as virus infection. This relatively unexplored area could yield important insights into the homeostatic control of immune cells in health and disease and facilitate the development of more effective immunotherapies. Consequently, tumour-suppressor genes are emerging as potential guardians of immune integrity.

Citing Articles

Combination adjuvant improves influenza virus immunity by downregulation of immune homeostasis genes in lymphocytes.

Dollinger E, Hernandez-Davies J, Felgner J, Jain A, Hwang M, Strahsburger E Immunohorizons. 2025; 9(2).

PMID: 39849993 PMC: 11841980. DOI: 10.1093/immhor/vlae007.

Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects.

Hsiao Y, Hsieh M, Chang G, Hsu Y, Wang C, Chen Y Cell Death Dis. 2025; 16(1):38.

PMID: 39843434 PMC: 11754596. DOI: 10.1038/s41419-025-07346-0.

A novel liquid-liquid phase separation-related gene signature for predicting prognosis in colon cancer.

Wang S, Hou S, Jiang S, Wang C, Zhang P, Ye Y Front Immunol. 2025; 15:1514613.

PMID: 39749343 PMC: 11693697. DOI: 10.3389/fimmu.2024.1514613.

T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia.

Badar T, Knutson K, Knutson K, Foran J, Foran J, Gangat N Blood Adv. 2024; 9(2):239-243.

PMID: 39571168 PMC: 11782860. DOI: 10.1182/bloodadvances.2024014553.

TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species-Dependent Cell Signaling Alterations.

Silwal A, Reese B, Patel B, Li Y, Kolev M, La-Beck N J Immunol. 2024; 213(12):1844-1857.

PMID: 39451031 PMC: 11611636. DOI: 10.4049/jimmunol.2400212.

References

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

He X, Xiang C, Zhang C, Xie Y, Chen L, Zhang G . p53 in the Myeloid Lineage Modulates an Inflammatory Microenvironment Limiting Initiation and Invasion of Intestinal Tumors. Cell Rep. 2015; 13(5):888-97. DOI: 10.1016/j.celrep.2015.09.045. View

Jones R, Plas D, Kubek S, Buzzai M, Mu J, Xu Y . AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005; 18(3):283-93. DOI: 10.1016/j.molcel.2005.03.027. View

Menendez D, Shatz M, Resnick M . Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol. 2012; 25(1):85-92. DOI: 10.1097/CCO.0b013e32835b6386. View

Sherr C . Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006; 6(9):663-73. DOI: 10.1038/nrc1954. View

Jeong J, Jo A, Park P, Lee H, Lee H . Brca2 deficiency leads to T cell loss and immune dysfunction. Mol Cells. 2015; 38(3):251-8. PMC: 4363725. DOI: 10.14348/molcells.2015.2302. View

Knudsen E, Knudsen K . Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer. 2009; 8(9):714-24. PMC: 2914856. DOI: 10.1038/nrc2401. View

Higuchi T, Flies D, Marjon N, Mantia-Smaldone G, Ronner L, Gimotty P . CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res. 2015; 3(11):1257-68. PMC: 4984269. DOI: 10.1158/2326-6066.CIR-15-0044. View

Balikova A, Jaager K, Viil J, Maimets T, Kadaja-Saarepuu L . Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells. Int J Oncol. 2012; 41(1):299-309. DOI: 10.3892/ijo.2012.1440. View

10.

Zitvogel L, Galluzzi L, Kepp O, Smyth M, Kroemer G . Type I interferons in anticancer immunity. Nat Rev Immunol. 2015; 15(7):405-14. DOI: 10.1038/nri3845. View

11.

Chaffer C, Weinberg R . How does multistep tumorigenesis really proceed?. Cancer Discov. 2015; 5(1):22-4. PMC: 4295623. DOI: 10.1158/2159-8290.CD-14-0788. View

12.

Zou W, Wolchok J, Chen L . PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016; 8(328):328rv4. PMC: 4859220. DOI: 10.1126/scitranslmed.aad7118. View

13.

Gay N, Symmons M, Gangloff M, Bryant C . Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol. 2014; 14(8):546-58. DOI: 10.1038/nri3713. View

14.

Gudkov A, Gurova K, Komarova E . Inflammation and p53: A Tale of Two Stresses. Genes Cancer. 2011; 2(4):503-16. PMC: 3135644. DOI: 10.1177/1947601911409747. View

15.

Liu G, Park Y, Tsuruta Y, Lorne E, Abraham E . p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury. J Immunol. 2009; 182(8):5063-71. DOI: 10.4049/jimmunol.0803526. View

16.

Hutcheson J, Witkiewicz A, Knudsen E . The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle. 2015; 14(24):3812-9. PMC: 4825764. DOI: 10.1080/15384101.2015.1010922. View

17.

Pampin M, Simonin Y, Blondel B, Percherancier Y, Chelbi-Alix M . Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J Virol. 2006; 80(17):8582-92. PMC: 1563870. DOI: 10.1128/JVI.00031-06. View

18.

Jung D, Jin D, Hong S, Kim J, Shin J, Kim D . Foxp3 expression in p53-dependent DNA damage responses. J Biol Chem. 2010; 285(11):7995-8002. PMC: 2832950. DOI: 10.1074/jbc.M109.047985. View

19.

Liu X, Karnell J, Yin B, Zhang R, Zhang J, Li P . Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J Clin Invest. 2010; 120(7):2497-507. PMC: 2898609. DOI: 10.1172/JCI42382. View

20.

Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H . Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003; 424(6948):516-23. DOI: 10.1038/nature01850. View